Evaluation of the anxiolytic properties of benzimidazole-2-thioethanones, 2-alkylthio- and 2-alkylsulfonylbenzimidazoles

Authors

DOI:

https://doi.org/10.18413/rrpharmacology.12.1156

Abstract

Introduction: Fabomotizole is an anxyolytic drug produced in Russia, a 2-mercaptobenzimidazole derivative. The pleiotropic effects of the benzimidazole scaffold, combined with proven neuropsychotropic properties, make fabomotizole a promising target for the synthesis of its analogs to obtain new derivatives with pronounced biological activity.

Materials and Methods: The study involved 125 white outbred male mice, randomly divided into 25 experimental groups (n=5). Twenty-one derivatives of benzimidazole-2-thioethanone, 2-alkylthio-, and 2-alkylsulfonylbenzimidazole were studied. The screening dose was calculated at the level of 1/100 of LD50, determined in silico by the consensus ADMET prediction. The behavioral patterns of the animals were assessed in vivo in Light/Dark Box and Open Field in comparison with etifoxine (50 mg/kg), fabomotizole (20 mg/kg), and phenazepam (0.01 mg/kg). In the final stage, the studied structures were optimized using quantum chemistry methods for subsequent analysis of the structure-activity relationship.

Results and Discussion: The most active derivatives of 2-mercaptobenzimidazole were derivatives of 5-unsubstituted-2-mercaptobenzimidazole: ZH-2, ZH-3, ZH-4, and ZH-41. Among all the studied compounds, a decrease in anxiolytic effect was observed in sequence: 5-unsubstituted – 5-chloro-substituted – 5-methoxy-substituted 2-mercaptobenzimidazoles. A study of the mercaptobenzimidazole fragment using molecular mechanics and quantum chemistry methods revealed that the addition of a substituent to the benzene ring leads to a redistribution of the electron density of cyclic structures.

Conclusion: The synthesis of new molecules with a putative anxiolytic effect based on 2-mercaptobenzimidazole is a promising direction in medicinal chemistry. The most active compounds are those without a substituent at position 5 of the benzimidazole ring.

Graphical Abstract

Keywords:

Open Field, Light/Dark Box, ADMET, 2-mercaptobenzimidazole, quantum chemistry, afobazole, phenazepam, etifoxine

References

Alwaili MA, Abu-Almakarem AS, Aljohani S, Alkhodair SA, Al-Bazi MM, Eid TM, Alamri J, Mobasher MA, Algarzae NK, A Khayyat AI, Alshaygy LS, El-Said KS (2024) Avenanthramide-C ameliorate doxorubicin-induced hepatotoxicity via modulating Akt/GSK-3β and Wnt-4/β-Catenin pathways in male rats. Frontiers in Molecular Biosciences 11: 1507786. https://doi.org/10.3389/fmolb.2024.1507786 [PubMed] [PMC]

Alzhrani ZMM, Alam MM, Nazreen S (2022) Recent advancements on benzimidazole: A versatile scaffold in medicinal chemistry. Mini Reviews in Medicinal Chemistry 22(2): 365–386. https://doi.org/10.2174/1389557521666210331163810 [PubMed]

da Silva DM, Sanz G, Vaz BG, de Carvalho FS, Lião LM, de Oliveira DR, da Silva Moreira LK, Cardoso CS, de Brito AF, da Silva DPB, da Rocha FF, Santana IGC, Galdino PM, Costa EA, Menegatti R (2018) Tert-butyl 4-((1-phenyl-1H-pyrazol-4-yl) methyl) piperazine-1-carboxylate (LQFM104) – New piperazine derivative with antianxiety and antidepressant-like effects: Putative role of serotonergic system. Biomedicine & Pharmacotherapy 103: 546–552. https://doi.org/10.1016/j.biopha.2018.04.077 [PubMed]

Dabburu GR, Garg A, Singhal N, Kumar M (2025) Afobazole: a potential drug candidate which can inhibit SARS CoV-2 and mimicry of the human respiratory pacemaker protein. In Silico Pharmacology 13(1): 30. https://doi.org/10.1007/s40203-025-00316-6 [PubMed][PMC]

Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 7(1): 1–13 [PubMed] [PMC]

Dong J, Wang NN, Yao ZJ, Zhang L, Cheng Y, Ouyang D, Lu AP, Cao DS (2018) ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. Journal of Cheminformatics 10(1): 29. [PubMed] [PMC]

Campos-Cardoso R, Godoy LD, Lazarini-Lopes W, Novaes LS, Dos Santos NB, Perfetti JG, Garcia-Cairasco N, Munhoz CD, Padovan CM (2023) Exploring the light/dark box test: Protocols and implications for neuroscience research. Journal of Neuroscience Methods 384: 109748. https://doi.org/10.1016/j.jneumeth.2022.109748 [PubMed]

Kapitsa IG, Alymov AA, Savinkova EV, Voronina TA, Seredenin SB (2023) Experimental study of antidepressant properties of afobazole. Bulletin of Experimental Biology and Medicine 175(1): 59–62. https://doi.org/10.1007/s10517-023-05811-4 [PubMed]

Kryzhanovskii SA, Antipova TA, Vititnova MB, Nikolaev SV, Durnev AD (2021) Angiogenic effects of anxiolytic fabomotizole. Doklady. Biochemistry and Biophysics 497(1): 63–65. https://doi.org/10.1134/S1607672921020101 [PubMed]

Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry 58(9): 4066–4072 [PubMed] [PMC]

Spasov AA, Zhukovskaya ON, Maltsev DV, Miroshnikov MV, Skripka MO, Sultanova KT, Morkovnik AS (2020) Anxiolytic activity of 11h-2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole and 2-mercaptobenzimizadole derivatives. Russian Journal of Bioorganic Chemistry 46(1): 107–114. https://doi.org/10.1134/S1068162020010124

Stewart JJP (2013) Optimization of parameters for semiempirical methods VI: More modifications to the NDDO approximations and re-optimization of parameters. Journal of Molecular Modeling 19: 1–32. [PubMed] [PMC]

Vasava MS, Bhoi MN, Rathwa SK, Jethava DJ, Acharya PT, Patel DB, Patel HD (2020) Benzimidazole: A milestone in the field of medicinal chemistry. Mini Reviews in Medicinal Chemistry 20(7): 532–565. https://doi.org/10.2174/1389557519666191122125453[PubMed]

Voronin MV, Kadnikov IA, Voronkov DN, Seredenin SB (2019) Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease. Scientific Reports 9(1): 17020. https://doi.org/10.1038/s41598-019-53413-w [PubMed] [PMC]

Wahba AS, Asal DM, Mesbah NM, Abo-Elmatty DM, Hazem RM, Abdel-Hamed AR (2025) Afobazole alleviates streptozotocin-induced diabetic nephropathy in rats via hypoglycemic, antioxidant, anti-inflammatory, and anti-apoptotic properties: Role of the S1R/Nrf2 antioxidant axis. Life Sciences 363: 123410. https://doi.org/10.1016/j.lfs.2025.123410[PubMed]

Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z, Li W, Liu G, Tang Y (2019) admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics (Oxford, England) 35(6): 1067–1069. https://doi.org/10.1093/bioinformatics/bty707[PubMed]

Author Contribution

Dmitriy V. Maltsev, Volgograd State Medical University

Doctor of Biological Sciences, Associate Professor, Professor in the Department of Pharmacology and Bioinformatics, Volgograd State Medical University; Head of the Laboratory of Anxiolytic and Antidepressant Drugs, Research Center for Innovative Medicines, Volgograd, Russia; e-mail: maltsevdmitriy@rambler.ru;ORCID ID: https://orcid.org/0000-0002-2005-6621. Author defined the research idea, developed the study design, and was the project administrator.

Kristina I. Adzhienko, Volgograd State Medical University

Assistant Professor in the Department of Pharmacology and Bioinformatics, Volgograd State Medical University; Junior Researcher in the Laboratory of Anxiolytic and Antidepressant Drugs, Research Center for Innovative Medicines, Volgograd, Russia; e-mail: kris959688@yandex.ru; ORCID ID: https://orcid.org/0009-0003-2860-8456. Author took part in experimental work in vivo.

Maxim A. Perfiliev , Volgograd State Medical University

PhD, Assistant Professor, Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Ministry of Health of the Russian Federation; Junior Researcher, Laboratory of Anxiolytic and Antidepressant Drugs, Volgograd State Medical University

Dmitriy A. Nekrasov, Volgograd State Medical University

MD, Junior Researcher, Laboratory of Anxiolytic and Antidepressant Drugs, Volgograd State Medical University, Volgograd, Russia; e-mail: dmitiynekrasov@mail.ru; ORCID ID: https://orcid.org/0000-0002-1722-011X. Author took part in experimental work in vivo.

Maria O. Maltseva, Volgograd State Medical University

PhD in Medicine, Associate Professor, Department of Surgical Dentistry and Maxillofacial Surgery, Volgograd State Medical University, Volgograd, Russia; e-mail: maltseva.volsmu@mail.ru; ORCID ID: https://orcid.org/0000-0002-4173-7143. Author performed statistical analysis, wrote and revised the manuscript.

Karina R. Magomedova , Volgograd State Medical University

Assistant Lecturer, Department of Pharmacology and Bioinformatics, Volgograd State Medical University; Junior Researcher, Laboratory of Anxiolytic and Antidepressant Drugs, Research Center for Innovative Medicines, Volgograd, Russia; e-mail: kerryreich666@gmail.com. Author took part in experimental work in vivo.

Raul I. Musaev , Volgograd State Medical University

Assistant Lecturer, Department of Pharmacology and Bioinformatics, Volgograd State Medical University; Junior Researcher, Laboratory of Anxiolytic and Antidepressant Drugs, Research Center for Innovative Medicines, Volgograd, Russia; e-mail: raulraulraul76@gmail.com; ORCID ID: https://orcid.org/0009-0006-3973-0184. Author took part in experimental work in vivo.

Pavel M. Vassiliev , Volgograd State Medical University

Doctor of Biological Sciences, Full Professor, Department of Pharmacology and Bioinformatics, Volgograd State Medical University; Head of the Laboratory of Information Technologies in Pharmacology and Computer Modeling of Drugs, Research Center for Innovative Medicines, Volgograd, Russia;e-mail: pvassilev@mail.ru; ORCID ID: https://orcid.org/0000-0002-8188-5052. Author provided in silico structure-activity relationships.

Olga N. Zhukovskaya , Southern Federal University

PhD in Chemistry, Senior Researcher, Department of Chemistry of Heterocyclic Compounds, Institute of Physical and Organic Chemistry, Southern Federal University, Rostov-on-Don, Russia; e-mail: ol@yandex.ru; ORCID ID: https://orcid.org/0000-0003-2485-2139. Author designed and synthesized the substances.

Alexander A. Spasov , Volgograd State Medical University

Honored Scientist of the Russian Federation, Full member of the Russian Academy of Sciences, Doctor Habil. of Medical Sciences, Full Professor, Head of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; e-mail: aspasov@mail.ru; ORCID ID: https://orcid.org/0000-0002-7185-4826. Author was the principal investigator of the study.

Downloads

Published

30-09-2026

How to Cite

Maltsev DV, Adzhienko KI, Perfiliev MA, Nekrasov DA, Maltseva MO, Magomedova KR, Musaev RI, Vassiliev PM, Zhukovskaya ON, Spasov AA (2026) Evaluation of the anxiolytic properties of benzimidazole-2-thioethanones, 2-alkylthio- and 2-alkylsulfonylbenzimidazoles. Research Results in Pharmacology 12(3): 91–103. https://doi.org/10.18413/rrpharmacology.12.1156

Issue

Section

Experimental Pharmacology

Most read articles by the same author(s)

<< < 1 2